firi-cel
firi-cel: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CARGO Therapeutics, Inc. (CRGX) | Phase 2 |
Clinical Trials (1)
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy
Frequently asked questions
Who is developing firi-cel?
firi-cel is being developed by CARGO Therapeutics, Inc..
How many clinical trials involve firi-cel?
BioSniper tracks 1 clinical trial involving firi-cel.
Get deeper analysis on firi-cel
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis